AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity

• Published in: PLoS pathogens 2015-08, Vol.11 (8), p.e1005090
• Main Authors: Fuchs, Sebastian P, Martinez-Navio, José M, Piatak, Jr, Michael, Lifson, Jeffrey D, Gao, Guangping, Desrosiers, Ronald C
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Animals; Antibodies, Anti-Idiotypic - blood; Antibodies, Anti-Idiotypic - immunology; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - immunology; Antibodies, Viral - immunology; Colleges & universities; Dependovirus; Enzyme-Linked Immunosorbent Assay; Gene therapy; Genetic Vectors; Health aspects; HEK293 Cells; Host-virus relationships; Humans; Immune system; Immunoglobulin G - administration & dosage; Immunoglobulin G - immunology; Immunoglobulins; Infections; Injections, Intramuscular; Macaca mulatta; Monoclonal antibodies; Observations; SAIDS Vaccines - immunology; Simian Acquired Immunodeficiency Syndrome - immunology; Simian Acquired Immunodeficiency Syndrome - prevention & control; Simian immunodeficiency virus; Simian Immunodeficiency Virus - immunology; Transfection
• ISSN: 1553-7374; 1553-7366; 1553-7374
• DOI: 10.1371/journal.ppat.1005090

Long-term delivery of potent broadly-neutralizing antibodies is a promising approach for the prevention of HIV-1 infection. We used AAV vector intramuscularly to deliver anti-SIV monoclonal antibodies (mAbs) in IgG1 form to rhesus monkeys. Persisting levels of delivered mAb as high as 270 μg/ml were achieved. However, host antibody responses to the delivered antibody were observed in 9 of the 12 monkeys and these appeared to limit the concentration of delivered antibody that could be achieved. This is reflected in the wide range of delivered mAb concentrations that were achieved: 1-270 μg/ml. Following repeated, marginal dose, intravenous challenge with the difficult-to-neutralize SIVmac239, the six monkeys in the AAV-5L7 IgG1 mAb group showed clear protective effects despite the absence of detectable neutralizing activity against the challenge virus. The protective effects included: lowering of viral load at peak height; lowering of viral load at set point; delay in the time to peak viral load from the time of the infectious virus exposure. All of these effects were statistically significant. In addition, the monkey with the highest level of delivered 5L7 mAb completely resisted six successive SIVmac239 i.v. challenges, including a final challenge with a dose of 10 i.v. infectious units. Our results demonstrate the continued promise of this approach for the prevention of HIV-1 infection in people. However, the problem of anti-antibody responses will need to be understood and overcome for the promise of this approach to be effectively realized.